Featured Research

from universities, journals, and other organizations

Antibody-directed chemotherapy offers improved survival for some leukemia patients

Date:
February 22, 2011
Source:
Cardiff University
Summary:
Antibody-directed chemotherapy offers improved survival to particular sub-groups of leukemia sufferers, a new study has found.

Antibody-directed chemotherapy offers improved survival to particular sub-groups of leukemia sufferers, a Cardiff University-led study has found.

Related Articles


The findings suggest that the treatment may be effective for the majority of younger acute myeloid leukemia (AML) sufferers, who can be identified by genetic profiling.

The research team studied more than a thousand patients, predominantly under 60, who received a combination of chemotherapy and the drug Gemtuzumab Ozogamicin (commercial name Mylotarg).

The study found no overall difference in survival rates across the whole study group. However, once the patients were broken down by pre-determined sub-groups, the researchers found significant differences.

For patients whose chromosomes showed they were already at low risk, the team found that combined treatment delivered a marked survival advantage. There was no advantage for those at high risk, and a trend towards a benefit for those at intermediate risk. Around 70 per cent of patients were found to have a predicted improvement of 10 per cent of surviving for five years. A sub-group with Core Binding Factor (CBF) leukemia was found to have a particularly clear benefit from the treatment.

Professor Alan Burnett of Cardiff University's School of Medicine, who led the study, said: "We already know that Acute Myeloid Leukemia is a collection of diseases. Our study suggests that particular treatments may need to be targeted to these particular sub-groups. We have found that CBF patients have distinctly better survival chances, with few additional side-effects, if Mylotarg is combined with conventional chemotherapy. Further research is required into this prospect."

The research was supported by a grant from the Medical Research Council and conducted at hospitals across the UK and in Denmark. The findings have just been published in the Journal of Clinical Oncology and are also the subject of an editorial in the journal.


Story Source:

The above story is based on materials provided by Cardiff University. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. K. Burnett, R. K. Hills, D. Milligan, L. Kjeldsen, J. Kell, N. H. Russell, J. A. L. Yin, A. Hunter, A. H. Goldstone, K. Wheatley. Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial. Journal of Clinical Oncology, 2010; 29 (4): 369 DOI: 10.1200/JCO.2010.31.4310

Cite This Page:

Cardiff University. "Antibody-directed chemotherapy offers improved survival for some leukemia patients." ScienceDaily. ScienceDaily, 22 February 2011. <www.sciencedaily.com/releases/2011/02/110222123012.htm>.
Cardiff University. (2011, February 22). Antibody-directed chemotherapy offers improved survival for some leukemia patients. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2011/02/110222123012.htm
Cardiff University. "Antibody-directed chemotherapy offers improved survival for some leukemia patients." ScienceDaily. www.sciencedaily.com/releases/2011/02/110222123012.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins